Press Releases
22 December 2022
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV12 December 2022
Gilead Sciences Again Named to Dow Jones Sustainability World Index9 December 2022
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+_HER2- Metastatic Breast Cancer1 December 2022
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations31 October 2022
Gilead Sciences Announces Third Quarter 2022 Financial Results26 October 2022
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities25 August 2022
GILEAD ANNOUNCES FIRST GLOBAL REGULATORY APPROVAL OF SUNLENCA® (LENACAPAVIR), THE ONLY TWICE-YEARLY HIV TREATMENT OPTION16 August 2022
GILEAD TO ACQUIRE REMAINING WORLDWIDE RIGHTS OF TRODELVY®24 June 2022
INVESTIGATIONAL LENACAPAVIR RECEIVES POSITIVE CHMP OPINION FOR PEOPLE WITH MULTI-DRUG RESISTANT HIV29 April 2022
VEKLURY® (REMDESIVIR) IS FIRST AND ONLY APPROVED TREATMENT FOR PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WITH COVID-1922 April 2022
GILEAD STATEMENT ON WHO RECOMMENDATION OF VEKLURY® (REMDESIVIR) AND ACCELERATION OF PREQUALIFICATION SUBMISSION17 February 2022
Veklury® (Remdesivir) Retains Antiviral Activity against Omicron, Delta and Other Emergent Sars-Cov-2 Variants in Multiple in Vitro Studies21 January 2022
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression19 October 2021
Gilead Sciences Announces Veklury® Donations To Help Address The Ongoing Covid-19 Crisis In Indonesia And Armenia18 October 2021
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of Hiv-1 in Pediatric Populations22 September 2021
VEKLURY® (REMDESIVIR) Significantly Reduced Risk of Hospitalization in High-Risk Patients with Covid-1923 October 2020
U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (Remdesivir) for Treatment of COVID-1917 September 2020
Gilead Sciences to Acquire Immunomedics17 September 2020
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome28 August 2020
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization11 August 2020
China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)7 May 2020
Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir27 February 2020
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19For more information, contact us:
Public Affairs
+86 21 3893 4588
+86 21 3893 4588
infochina@gilead.com